GSK today welcomed the publication of the third Access to Medicine (ATM)
Index, which measures the performance of the top 20 pharmaceutical
companies on their efforts to improve access to medicine and healthcare in
developing countries. GSK has been ranked top of the Index in 2012 for the
third time of publishing, scoring highest in four categories including
general access to medicine management, research and development activity,
capability advancement and drug donation and philanthropy.
"In Ghana and across the continent, GSK is committed to finding new and
innovative ways to ensure access to medicine,"said Country Manager Menu
Otuo. "We are collaborating with government, NGOs and other
private-sector companies to improve people's health and well-being no
matter where they live, while continuing to expand our business and invest
in research."
Over the past five years, GSK has made fundamental changes to its business
model including re-investing 20 per cent of all profits in the least
developed countries to help communities strengthen their local health
infrastructure.
The Access to Medicine Index is a major initiative of the Access to
Medicine Foundation, an international not-for-profit organisation,
established in 2004 and dedicated to improving access to medicine. The
index ranks individual pharmaceutical companies on their efforts to
enhance global access to medicine across seven categories: drug donation
and philanthropy, capability advancement, patents and licensing, equitable
pricing, research and development, public policy, and general access to
medicine management.
The Index -the first of which was published in 2008, followed by a second
in 2010 - provides an overall ranking of 20 pharmaceutical companies who
are measured across a range of strategic and technical areas. It also
analyses industry trends in commitments, transparency, performance and
innovation.
GlaxoSmithKline -one of the world's leading research-based pharmaceutical
and healthcare companies -is committed to improving the quality of human
life by enabling people to do more, feel better and live longer. For
further information please visit www.gsk.com<http://www.gsk.com>
Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995, GSK cautions investors that any forward-looking
statements or projections made by GSK, including those made in this
announcement, are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Factors that may affect
GSK' s operations are described under 'Risk factors' in the 'Financial
review & risk' section in the company's Annual Report 2011 included as
exhibit 15.2 to the company's Annual Report on Form 20-F for 2011.